Bimokalner is an investigational new drug under evaluation for preventing and treating hearing loss caused by cisplatin treatment. It is a voltage-gated potassium channel agonist targeting Kv7.4 and is being developed by Acousia Therapeutics GmbH.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.